Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms.
about
A Review of Swertia chirayita (Gentianaceae) as a Traditional Medicinal PlantMaltodextrin-based proniosomesThe bitter barricading of prostaglandin biosynthesis pathway: understanding the molecular mechanism of selective cyclooxygenase-2 inhibition by amarogentin, a secoiridoid glycoside from Swertia chirayita.Clinical and experimental advances in treatment of visceral leishmaniasis.Delivery strategies for antiparasitics.Phytochemical investigation of crude methanol extracts of different species of Swertia from Nepal.Drug delivery strategies for therapy of visceral leishmaniasis.Drug resistance in leishmaniasis: current drug-delivery systems and future perspectives.Polymeric colloidal particulate systems: intelligent tools for intracellular targeting of antileishmanial cargos.Investigational drugs for visceral leishmaniasis.In Vitro Flower Induction from Shoots Regenerated from Cultured Axillary Buds of Endangered Medicinal Herb Swertia chirayita H. Karst.High-throughput sequencing and de novo transcriptome assembly of Swertia japonica to identify genes involved in the biosynthesis of therapeutic metabolites.Phytochemistry and Pharmacological Activities of the Genus Swertia (Gentianaceae): A Review.The Role of Natural Products in Drug Discovery and Development against Neglected Tropical Diseases.5-ALA-mediated photodynamic therapy reduces the parasite load in mice infected with Leishmania braziliensis.Liposomal formulations in the pharmacological treatment of leishmaniasis: a review.Amarogentin Induces Apoptosis of Liver Cancer Cells via Upregulation of p53 and Downregulation of Human Telomerase Reverse Transcriptase in Mice.Targeting of mannosylated liposome incorporated benzyl derivative of Penicillium nigricans derived compound MT81 to reticuloendothelial systems for the treatment of visceral leishmaniasis.Targeting of liposomal andrographolide to L. donovani-infected macrophages in vivo.Protective Effects of Amarogentin against Carbon Tetrachloride-Induced Liver Fibrosis in Mice.Critical evaluation of the therapeutic potential of bassic acid incorporated in oil-in-water microemulsions and poly-D,L-lactide nanoparticles against experimental leishmaniasis.Development of Nanoemulsions to Enhance the Antileishmanial Activity of Copaifera paupera Oleoresins.
P2860
Q26770438-9398D24B-B435-49F1-8DE0-CC77EAF1B50AQ28366138-0A4B3465-8B22-4669-BE7C-4745BDB2FEB9Q28540582-AF549656-58FD-43D2-BA36-92B94F09F381Q33982648-A213A747-9A83-49FF-9DD0-EA61E6C2CE39Q35056056-2E7D9D7E-155F-4430-8E89-1B808EE12CFAQ35879057-931F3F1F-40F3-44B6-ADC0-9E63A798DA96Q37702257-F7255F7E-9A06-4FDE-B47E-813DF14C8FBEQ38154347-5893C6DE-3DB8-420A-9107-31EE0E1850D5Q38154629-78391DCC-0564-4186-B5CD-A51D941C67C3Q38269581-9B2F8F25-14B8-47FA-9080-2B6D93E3EBE9Q38269964-CD19A405-60E7-4965-9E77-9057ABE212DAQ38445189-1CD18E00-97F7-4DC7-A7C4-AE9B477F4759Q38685528-71EFBCA9-FDF1-4EEA-A825-07B5B8B497E4Q38943630-F28F4D61-83E2-4AD9-B398-4340753E43E0Q40436132-40B70865-B866-4C20-A187-F9E21B3EEC99Q43168913-739BEE46-5FD9-4D45-8E7A-4908093C24B5Q43262045-FB391E4C-A8D5-4363-B132-4A86E56D0A5EQ46731824-433C5230-7FC6-4166-8E5B-E89B0F7FEAE2Q50506874-8AC4E3DE-8179-49AE-B640-F2D39261D524Q51015593-D27BB7FC-CF64-4D38-9F2C-0B9FCE369013Q51806767-5A894D58-003B-4BF1-A107-A8667809D7F9Q54940762-85D0AA21-E38A-4173-84D9-018716AF1131
P2860
Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Evaluation of the in-vivo acti ...... liposomal and niosomal forms.
@ast
Evaluation of the in-vivo acti ...... liposomal and niosomal forms.
@en
type
label
Evaluation of the in-vivo acti ...... liposomal and niosomal forms.
@ast
Evaluation of the in-vivo acti ...... liposomal and niosomal forms.
@en
prefLabel
Evaluation of the in-vivo acti ...... liposomal and niosomal forms.
@ast
Evaluation of the in-vivo acti ...... liposomal and niosomal forms.
@en
P2093
P356
P1476
Evaluation of the in-vivo acti ...... liposomal and niosomal forms.
@en
P2093
P304
P356
10.1093/JAC/44.6.791
P407
P577
1999-12-01T00:00:00Z